BIOR - Biora Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
BIOR price evolution
BIOR
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.87 | $0.82 | $0.82 | $0.83 |
| Inventory | ||||
| Total current assets | $6.05 | $9.2 | $14.07 | $19.07 |
| Long term investments | ||||
| Property, plant & equipment | $2.19 | $2.48 | $2.55 | $2.77 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $14.51 | $18.26 | $22.99 | $31.21 |
| Current liabilities | ||||
| Accounts payable | $6.92 | $7.51 | $4.94 | $2.84 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $120.62 | $45.99 | $51.1 | $62.97 |
| Long term debt | $43.77 | $43.28 | $43.74 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $121.13 | $107.58 | $123.17 | $132.64 |
| Shareholders' equity | ||||
| Retained earnings | -$967.08 | -$948.68 | -$955.15 | -$950.96 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.83 | $0.83 | $0.65 | $6.63 |
| Inventory | $12.22 | |||
| Total current assets | $19.07 | $38.12 | $98.43 | $126.34 |
| Long term investments | ||||
| Property, plant & equipment | $2.77 | $3.14 | $4.01 | $8.11 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $31.21 | $53.52 | $108.84 | $154.44 |
| Current liabilities | ||||
| Accounts payable | $2.84 | $3.61 | $8.71 | $17.38 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $62.97 | $23.3 | $61.61 | $72.67 |
| Long term debt | $43.74 | $127.81 | $126.39 | $160.2 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $132.64 | $155.81 | $193.81 | $261.43 |
| Shareholders' equity | ||||
| Retained earnings | -$950.96 | -$826.84 | -$788.69 | -$541.27 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.03 | $0.32 | $0.54 | |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $16.26 | $16.1 | $16.06 | $13.34 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.04 | -$0.07 | $0.05 | -$0.1 |
| Interest expense | $6.24 | $12.29 | $9.76 | $10.89 |
| Net income | ||||
| Net income | -$18.4 | $6.46 | -$4.19 | -$15.41 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0 | $0.3 | $1.25 | $0.16 |
| Cost of revenue | ||||
| Gross Profit | $1.25 | $0.16 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $67.15 | $62.1 | $119.08 | $107.78 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.09 | -$0.4 | -$0.12 | -$37.53 |
| Interest expense | $1.29 | $15.6 | -$66.79 | -$9.91 |
| Net income | ||||
| Net income | -$124.11 | -$38.2 | -$247.41 | -$192.53 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $2.81 | $2.83 | $3 | $2.44 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $17.36 | $10.74 | $5.1 | $30.78 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$12.01 | -$9.89 | -$4.39 | -$15.28 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $2.44 | -$0.79 | -$1.24 | -$4.94 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $30.78 | $7.3 | $165.05 | $229.72 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$15.28 | -$57.91 | -$3.68 | $59.04 |
News
Fundamentals
| Market cap | $809.10K |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 3.68M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$31.54M |
| Revenue Q/Q | -60.00% |
| Revenue Y/Y | N/A |
| P/E ratio | -0.03 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$8.58 |
|---|---|
| ROA | -145.05% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.05 |
| Quick ratio | N/A |